Arsenic-induced cancers: A review with special reference to gene, environment and their interaction

Genes and Environment

Volumn 33, Issue 4, 2011, Pages 128-140

  Banerjee, Mayukh ^a   Bhattacharjee, Pritha ^a   Giri, Ashok K ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Arsenic; Cancer; Diet; Gene environment interaction

Indexed keywords

EID: 82755186877     PISSN: 18807046     EISSN: 18807062     Source Type: Journal    
DOI: 10.3123/jemsge.33.128     Document Type: Conference Paper

References (200)

1. Mondal D, Banerjee M, Kundu M, Banerjee N, Bhattacharya U, Giri AK, Ganguli B, Sen Roy S, Polya DA. Comparison of drinking water, raw rice and cooking of rice as arsenic exposure routes in three contrasting areas of West Bengal, India. Environ Geochem Health. 2010; 32: 463-477.
2. Polya DA, Charlet L. Rising arsenic risk? Nature Geoscience. 2009; 2: 383-384.
3. IARC. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans: some drinking water disinfectants and contaminants, including arsenic. IARC Sci Publ. 2004; 84: 1-477.
4. ATSDR. CERCLA list of hazardous substances [Accessed at: http://wwwatsdrcdcgov/cercla/07listhtml, Accessed on 17032011]
5. Trepka MJ, Heinrich J, Schulz C, Krause C, Popescu M,Wjst M,Wichmann HE. Arsenic burden among children in industrial areas of eastern Germany. Sci Total Environ 1996; 180: 95-105. (Pubitemid 26072847)
6. Hysong TA, Burgess JL, Cebrián Garcia ME, O'Rourke MK. House dust and inorganic urinary arsenic in two Arizona mining towns. J Expo Anal Environ Epidemiol. 2003; 13: 211-218. (Pubitemid 36753836)
7. Tollestrup K, Frost FJ, Harter LC, McMillan GP. Mortality among children residing near the American Smelting and Refining Company (ASARCO) copper smelter in Ruston, Washington. Arch Environ Health. 2003; 58: 683-691. (Pubitemid 40096821)
8. Paiva L, Martínez V, Creus A, Quinteros D, Marcos R. Sister chromatid exchange analysis in smelting plant workers exposed to arsenic. Environ Mol Mutagen. 2006; 47: 230-235.
9. Paiva L, Martínez V, Creus A, Quinteros D, Marcos R. Evaluation of micronucleus frequencies in blood lymphocytes from smelting plant workers exposed to arsenic. Environ Mol Mutagen. 2008; 49: 200-205. (Pubitemid 351499910)
10. Vuyyuri SB, Ishaq M, Kuppala D, Grover P, Ahuja YR. Evaluation of micronucleus frequencies and DNA damage in glass workers exposed to arsenic. Environ Mol Mutagen. 2006; 47: 562-570. (Pubitemid 44291169)
11. Apostoli P, Bartoli D, Alessio L, Buchet JP. Biological monitoring of occupational exposure to inorganic arsenic. Occup Environ Med. 1999; 56: 825-832.
12. Edelman P. Environmental and workplace contamination in the semiconductor industry: implications for future health of the workforce and community. Environ Health Perspect. 1990; 86: 291-295. (Pubitemid 20298849)
13. Hwang YH, Lee ZY,Wang JD, Hsueh YM, Lu IC, Yao WL. Monitoring of arsenic exposure with speciated urinary inorganic arsenic metabolites for ion implanter maintenance engineers. Environ Res. 2002; 90: 207-216.
14. Liao YH, Yu HS, Ho CK, Wu MT, Yang CY, Chen JR, Chang CC. Biological monitoring of exposures to aluminium, gallium, indium, arsenic, and antimony in optoelectronic industry workers. J Occup Environ Med. 2004; 46: 931-936.
15. Hu CW, Pan CH, Huang YL, Wu MT, Chang LW, Wang CJ, Chao MR. Effects of arsenic exposure among semiconductor workers: a cautionary note on urinary 8- oxo-7,8-dihydro-2'-deoxyguanosine. Free Radic Biol Med. 2006; 40: 1273-1278.
16. Chou WC, Chio CP, Liao CM. Assessing airborne PMbound arsenic exposure risk in semiconductor manufacturing facilities. J Hazard Mater. 2009; 167: 976-986.
17. Park D, Yang H, Jeong J, Ha K, Choi S, Kim C, Yoon C, Park D, Paek D. A comprehensive review of arsenic levels in the semiconductor manufacturing industry. Ann Occup Hyg. 2010; 54: 869-879.
18. Bencko V, Symon K, Stálnik L, Bátora J, Vanco E, SvandováE. Rate of malignant tumor mortality among coal burning power plant workers occupationally exposed to arsenic. J Hyg Epidemiol Microbiol Immunol. 1980; 24: 278-284. (Pubitemid 11160983)
19. Pesch B, Ranft U, Jakubis P, Nieuwenhuijsen MJ, Hergemöller A, Unfried K, Jakubis M, Miskovic P, Keegan T. Environmental arsenic exposure from a coal-burning power plant as a potential risk factor for nonmelanoma skin carcinoma: results from a case-control study in the district of Prievidza, Slovakia. Am J Epidemiol. 2002; 155: 798-809. (Pubitemid 34456990)
20. Wagner SL, Weswig P. Arsenic in blood and urine of forest workers as indices of exposure to cacodylic acid. Arch Environ Health. 1974; 28: 77-79.
21. Peoples SA, Maddy KT, Peifer WR, Edmiston S. Occupational exposures to pesticides containing organoarsenicals in California. Vet Hum Toxicol. 1979; 21: 417-421. (Pubitemid 10219214)
22. Mabuchi K, Lilienfeld AM, Snell LM. Cancer and occupational exposure to arsenic: a study of pesticide workers. Prev Med. 1980; 9: 51-77. (Pubitemid 10176381)
23. Miller CS, Hoover WL, Culver WH. Exposure of pesticide applicators to arsenic acid. Arch Environ Contam Toxicol. 1980; 9: 281-288. (Pubitemid 10156527)
24. Wojeck GA, Nigg HN, Braman RS, Stamper JH, Rouseff RL. Worker exposure to arsenic in Florida grapefruit spray operations. Arch Environ Contam Toxicol. 1982; 11: 661-667. (Pubitemid 13168200)
25. Abdelghani AA, Anderson AC, Jaghabir M, Mather F. Arsenic levels in blood, urine, and hair of workers applying monosodium methanearsonate (MSMA). Arch Environ Health. 1986; 41: 163-169. (Pubitemid 16014014)
26. Dennis LK, Lynch CF, Sandler DP, Alavanja MC. Pesticide use and cutaneous melanoma in pesticide applicators in the agricultural heath study. Environ Health Perspect. 2010; 118: 812-817.
27. Tseng WP. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect. 1977; 19: 109-119. (Pubitemid 8182684)
28. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985; 45: 5895-5899.
29. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer. 1986; 53: 399-405.
30. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989; 130: 1123-1132.
31. Zaldívar R. A morbid condition involving cardio-vascular, broncho-pulmonary, digestive and neural lesions in children and young adults after dietary arsenic exposure. Zentralbl Bakteriol B. 1980; 170: 44-56. (Pubitemid 10032067)
32. Zaldívar R, Prunés L, Ghai GL. Arsenic dose in patients with cutaneous carcinomata and hepatic hemangio-endothelioma after environmental and occupational exposure. Arch Toxicol. 1981; 47: 145-54. (Pubitemid 11098857)
33. Saha KC. Melanokeratosis from arsenic contaminated tubewell water. Indian J Dermatol. 1984; 29: 37-46.
34. Groundwater Studies for Arsenic Contamination in Bangladesh Phase I: Rapid Investigation Phase, Final Report, Main Report, British Geological Survey, Mott MacDonald Ltd (UK), January 1999.
35. Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT. A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol. 1995; 293: 455-462. (Pubitemid 3006685)
36. Feng Z, Xia Y, Tian D, Wu K, Schmitt M, Kwok RK, Mumford JL. DNA damage in buccal epithelial cells from individuals chronically exposed to arsenic via drinking water in Inner Mongolia, China. Anticancer Res. 2001; 21: 51-57.
37. Mukherjee A, Sengupta MK, Hossain MA, Ahamed S, Das B, Nayak B, Lodh D, Rahman MM, Chakraborti D. Arsenic contamination in groundwater: a global perspective with emphasis on the Asian scenario. J Health Popul Nutr. 2006; 24: 142-163. (Pubitemid 46151820)
38. Garelick H, Jones H, Dybowska A, Valsami-Jones E. Arsenic pollution sources. Rev Environ Contam Toxicol. 2008; 197: 17-60.
39. Bencko V, Symon K. Test of environmental exposure to arsenic and hearing changes in exposed children. Environ Health Perspect. 1977; 19: 95-101. (Pubitemid 8182681)
40. Liu J, Zheng B, Aposhian HV, Zhou Y, Chen ML, Zhang A, Waalkes MP. Chronic arsenic poisoning from burning high-arsenic-containing coal in Guizhou, China. Environ Health Perspect. 2002; 110: 119-122. (Pubitemid 34163025)
41. Guha Mazumder DN, Haque R, Ghosh N, De BK, Santra A, Chakraborti D, Smith AH. Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. Int J Epidemiol. 2000; 29: 1047-1052. (Pubitemid 32007641)
42. Hossain MK, Khan MM, Alam MA, Chowdhury AK, Delwar Hossain M, Feroze Ahmed M, Kobayashi K, Sakauchi F, Mori M. Manifestation of arsenicosis patients and factors determining the duration of arsenic symptoms in Bangladesh. Toxicol Appl Pharmacol. 2005; 208: 78-86. (Pubitemid 41309051)
43. Baidya K, Raj A, Mondal L, BhaduriG, TodaniA. Persistent conjunctivitis associated with drinking arseniccontaminated water. J Ocul Pharmacol Ther. 2006; 22: 208-211. (Pubitemid 44051134)
44. Soto-Peña GA, Luna AL, Acosta-Saavedra L, Conde P, López-Carrillo L, Cebrián ME, Bastida M, Calderón- Aranda ES, Vega L. Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J. 2006; 20: 779-781. (Pubitemid 46671213)
45. Ghosh P, Banerjee M, De Chaudhuri S, Chowdhury R, Das JK,Mukherjee A, Sarkar AK,Mondal L, Baidya K, Sau TJ, Banerjee A, Basu A, Chaudhuri K, Ray K, Giri AK. Comparison of health effects between individuals with and without skin lesions in the population exposed to arsenic through drinking water in West Bengal, India. J Expo Sci Environ Epidemiol. 2007; 17: 215-223. (Pubitemid 46788895)
46. Hutchinson J. An address on the study of skin diseases as illustrating the doctrines of general pathology. Br Med J. 1887; 2: 229-232.
47. Rickert RR, Brodkin RH, Hutter RV. Bowen's disease. CA Cancer J Clin. 1977; 27: 160-166. (Pubitemid 8115609)
48. Graham JH, Mazzanti GR, Helwig EB. Chemistry of Bowen's disease: relationship to arsenic. J Invest Derm. 1961; 37: 317-332.
49. Imamura S, Odaka T. Multiple Bowen's disease seen in a localized district, especially on etiologic significance of arsenic. Hifuka Kiyo. 1962; 57: 99-115.
50. Yeh S, How SW, Lin CS. Arsenical cancer of skin: Histologic study with special reference to Bowen's disease. Cancer. 1968; 21: 312-339.
51. Yeh S, Chen HC, How SW, Deng CS. Fine structure of Bowen's disease in chronic arsenicalism. J Natl Cancer Inst. 1974; 53: 31-44.
52. Hamada T, Horiguchi S. Occupational chronic arsenical poisoning on the cutaneous manifestations. Sangyo Igaku. 1976; 18: 103-115.
53. Koh E, Kondoh N, Kaihara H, Fujioka H, Kitamura K. Ureteral tumor with multiple Bowen's disease forty-two years after exposure to arsenic. Eur Urol. 1989; 16: 398-400. (Pubitemid 19214909)
54. Tsuda T, Nagira T, Yamamoto M, Kume Y. An epidemiological study on cancer in certified arsenic poisoning patients in Toroku. Ind Health. 1990; 28: 53-62. (Pubitemid 20263671)
55. Matsui M, Nishigori C, Toyokuni S, Takada J, Akaboshi M, Ishikawa M, Imamura S, Miyachi Y. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2'-deoxyguanosine in arsenic-related Bowen's disease. J Invest Dermatol. 1999; 113: 26-31. (Pubitemid 29328154)
56. Leong GK, Stone JL, Farmer ER, Scotto J, Reizner GT, Burnett TS, Elpern DJ. Nonmelanoma skin cancer in Japanese residents of Kauai, Hawaii. J Am Acad Dermatol. 1987; 17: 233-238. (Pubitemid 17121044)
57. Foy HM, Tarmapai S, Eamchan P, Metdilogkul O. Chronic arsenic poisoning from well water in a mining area in Thailand. Asia Pac J Public Health. 1992-1993; 6: 150-152.
58. Yu HS, Chang KL, Wang CM, Yu CL J. Alterations of mitogenic responses of mononuclear cells by arsenic in arsenical skin cancers. Dermatol. 1992; 19: 710-714
59. Kuo TT, Hu S, Lo SK, Chan HL. p53 expression and proliferative activity in Bowen's disease with or without chronic arsenic exposure. Hum Pathol. 1997; 28: 786-790. (Pubitemid 27298962)
60. Castrén K, Ranki A, Welsh JA, Vähäkangas KH. Infrequent p53 mutations in arsenic-related skin lesions. Oncol Res. 1998; 10: 475-82. (Pubitemid 128740441)
61. Cöl M, Cöl C, Soran A, Sayli BS, Oztürk S. Arsenicrelated Bowen's disease, palmar keratosis, and skin cancer. Environ Health Perspect. 1999; 107: 687-689. (Pubitemid 29412783)
62. Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratosis and Bowen's disease with acitretin. Int J Dermatol. 2002; 41: 84-87. (Pubitemid 34552353)
63. Kim HJ, Min HG, Lee ES. Bowen's diseases and basal cell carcinomas in a patient. J Dermatol. 1999; 26: 695-697. (Pubitemid 29510355)
64. Park JY, Rim JH, Choe YB, Youn JI. Arsenic keratosis and pigmentation accompanied by multiple Bowen's disease and genitourinary cancer in a psoriasis patient. J Dermatol. 2002; 29: 446-451. (Pubitemid 34857583)
65. Rahman MM, Sengupta MK, Ahamed S, Chowdhury UK, Hossain MA, Das B, Lodh D, Saha KC, Pati S, Kaies I, Barua AK, Chakraborti D. The magnitude of arsenic contamination in groundwater and its health effects to the inhabitants of the Jalangi-one of the 85 arsenic affected blocks in West Bengal, India. Sci Total Environ. 2005; 338: 189-200. (Pubitemid 40248508)
66. Ghosh P, Banerjee M, De Chaudhuri S, Das JK, Sarma N, Basu A, Giri AK. Increased chromosome aberration frequencies in the Bowen's patients compared to noncancerous skin lesions individuals exposed to arsenic. Mutat Res. 2007; 632: 104-110. (Pubitemid 47031690)
67. Ghosh P, Basu A, Singh KK, Giri AK. Evaluation of cell types for assessment of cytogenetic damage in arsenic exposed population. Mol Cancer. 2008; 7: 45.
68. Ahmad SA, Maharjan M, Watanabe C, Ohtsuka R. Arsenicosis in two villages in Terai, lowland Nepal. Environ Sci. 2004; 11: 179-188.
69. Leibowitz MR, Rippey JJ, Thompson P. Fungating Bowen's disease with presumed arsenic intoxication A case report. S Afr Med J. 1982; 62: 737-739. (Pubitemid 13198522)
70. Hsu YH, Li SY, Chiou HY, Yeh PM, Liou JC, Hsueh YM, Chang SH, Chen CJ. Spontaneous and induced sister chromatid exchanges and delayed cell proliferation in peripheral lymphocytes of Bowen's disease patients and matched controls of arseniasis-hyperendemic villages in Taiwan. Mutat Res. 1997; 386: 241-251.
71. Hsu CH, Yang SA, Wang JY, Yu HS, Lin SR. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer. 1999; 80: 1080-1086.
72. Wang BJ, Lee YY, Mak CP, Kao HF, Hsu ML, Hsien JR. Quantitative and morphological changes of Langerhans cells in Bowen's disease from patients with chronic arsenicism. J Formos Med Assoc. 1991; 90: 1093-1098.
73. Yu HS, Chen GS, Sheu HM, Kao JS, Chang KL, Yu CL. Alterations of skin-associated lymphoid tissue in the carcinogenesis of arsenical skin cancer. Proc Natl Sci Counc Repub China B. 1992; 16: 17-22.
74. Sheu HM, Ko SS, Yu HS. Expression of keratin 16 in normal and lesional skin of solitary and multiple Bowen's disease using monoclonal antibody Ks 812 staining. J Formos Med Assoc. 1991; 90: 1252-1255.
75. Yu HS, Chiou KS, Chen GS, Yang RC, Chang SF. Progressive alterations of cytokeratin expressions in the process of chronic arsenism. J Dermatol. 1993; 20: 741-745.
76. Chang CH, Tsai RK, Chen GS, Yu HS, Chai CY. Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers. J Cutan Pathol. 1998; 25: 457-462.
77. Liao WT, Yu CL, Lan CC, Lee CH, Chang CH, Chang LW, You HL, Yu HS. Diffrential effcts of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease. Carcinogenesis. 2009; 30: 1064-1072.
78. Yu HS, Chang KL, Yu CL, Wu CS, Chen GS, Ho JC. Defective IL-2 receptor expression in lymphocytes of patients with arsenic-induced Bowen's disease. Yu Arch Dermatol Res. 1998; 290: 681-687.
79. Yu HS, Liao WT, Chang KL, Yu CL, Chen GS. Arsenic induces tumor necrosis factor alpha release and tumor necrosis factor receptor 1 signaling in T helper cell apoptosis. J Invest Dermatol. 2002; 119: 812-819.
80. Centeno JA, Mullick FG, Martinez L, Page NP, Gibb H, Longfellow D, Thompson C, Ladich ER. Pathology related to chronic arsenic exposure. Environ Health Perspect. 2002; 110 Suppl 5: 883-886. (Pubitemid 35276887)
81. Møller R, Nielsen A, Reymann F. Multiple basal cell carcinoma and internal malignant tumors. Arch Dermatol. 1975; 111: 584-585.
82. Jackson R, Grainge JW. Arsenic and cancer. Can Med Assoc J. 1975; 113: 396-401.
83. Morton W, Starr G, Pohl D, Stoner J, Wagner S, Weswig D. Skin cancer and water arsenic in Lane County, Oregon. Cancer. 1976; 37: 2523-2532.
84. Cabrera HN, Cuda G, López M, Costa JA. Basal cell epithelioma of the vulva in chronic endemic regional arsenic poisoning. Med Cutan Ibero Lat Am. 1984; 12: 81-85.
85. Tan SH, Tham SN, Goh CL. Skin cancers at Tertiary Referral Skin Hospital in Singapore. Int J Dermatol. 1995; 34: 770-776.
86. Wong SS, Tan KC, Goh CL. Cutaneous manifestations of chronic arsenicism: review of seventeen cases. J Am Acad Dermatol. 1998; 38 (2 Pt 1): 179-185.
87. BoonchaiW,Walsh M, Cummings M, Chenevix-Trench G. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch Dermatol. 2000; 136: 195-198. (Pubitemid 30090758)
88. Boonchai W, Green A, Ng J, Dicker A, Chenevix- Trench G. Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication. J Am Acad Dermatol. 2000; 43: 664-669.
89. Paul PC, Chattopadhyay A, Dutta SK, Mazumder DN, Santra A. Histopathology of skin lesions in chronic arsenic toxicity-grading of changes and study of proliferative markers. Indian J Pathol Microbiol. 2000; 43: 257-264.
90. Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, Greenberg ER. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol. 2001; 153: 559-565. (Pubitemid 32221710)
91. Cabrera HN, Gómez ML. Skin cancer induced by arsenic in the water. J Cutan Med Surg. 2003; 7: 106-111. (Pubitemid 36506158)
92. Thirumaran RK, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Goessler W, Vahter M, Leonardi GS, Clemens F, Fletcher T, Hemminki K, Kumar R. Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis. 2006; 27: 1676-1681. (Pubitemid 44288057)
93. Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HH. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect. 2007; 115: 1231-1236. (Pubitemid 351802357)
94. Robertson JW, Clement KW. Squamous cell carcinoma following prolonged use of arsenic; case report. Ohio Med. 1948; 44: 280.
95. Gustavsson P, Gustavsson A, Hogstedt C. Excess of cancer in Swedish chimney sweeps. Br J Ind Med. 1988; 45: 777-781. (Pubitemid 18266745)
96. Guo HR, Yu HS, Hu H, Monson RR. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control. 2001; 12: 909-916. (Pubitemid 34048872)
97. Fumal I, Piérard-Franchimont C, Piérard GE. Arsenical keratoses and carcinomas. Rev Med Liege. 2005; 60: 217-221. (Pubitemid 40712401)
98. Zhang A, Feng H, Yang G, Pan X, Jiang X, Huang X, Dong X, Yang D, Xie Y, Peng L, Jun L, Hu C, Jian L, Wang X. Unventilated indoor coal-fired stoves in Guizhou province, China: cellular and genetic damage in villagers exposed to arsenic in food and air. Environ Health Perspect. 2007; 115: 653-658. (Pubitemid 46585542)
99. Gawkrodger DJ. Occupational skin cancers. OccupMed (Lond). 2004; 54: 458-463. (Pubitemid 39462221)
100. Pershagen G. The carcinogenicity of arsenic. Environ Health Perspect. 1981; 40: 93-100. (Pubitemid 12231149)
101. Pi J, Diwan BA, Sun Y, Liu J, Qu W, He Y, Styblo M, Waalkes MP. Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med. 2008; 45: 651-658.
102. Sun Y, Pi J, Wang X, Tokar EJ, Liu J, Waalkes MP. Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. Toxicol. 2009; 262: 162-170.
103. Samuel HS. Arsenic and lung cancer. Br Med J. 1964; 1: 1656.
104. Pershagen G, Elinder CG, Bolander AM. Mortality in a region surrounding an arsenic emitting plant. Environ Health Perspect. 1977; 19: 133-137. (Pubitemid 8182688)
105. Axelson O, Dahlgren E, Jansson CD, Rehnlund SO. Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br J Ind Med. 1978; 35: 8-15. (Pubitemid 8355603)
106. Rom WN, Varley G, Lyon JL, Shopkow S. Lung cancer mortality among residents living near the El Paso smelter. Br J Ind Med. 1982; 39: 269-272. (Pubitemid 12045491)
107. Taylor PR, Qiao YL, Schatzkin A, Yao SX, Lubin J, Mao BL, Rao JY,McAdams M, Xuan XZ, Li JY. Relation of arsenic exposure to lung cancer among tin miners in Yunnan Province, China. Br J Ind Med. 1989; 46: 881-886. (Pubitemid 20004673)
108. Järup L, Pershagen G. Arsenic exposure, smoking, and lung cancer in smelter workers-a case-control study. Am J Epidemiol. 1991; 134: 545-51. Erratum in: Am J Epidemiol. 1992; 136: 1174.
109. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, Wood R, Kosnett MJ, Smith MT. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992; 97: 259-267.
110. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer. 1992; 66: 888-892.
111. Chiou HY, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS, Huang CH, Chen CJ. Incidence of internal cancers and ingested inorganic arsenic: a sevenyear follow-up study in Taiwan. Cancer Res. 1995; 55: 1296-1300.
112. Ferreccio C, González Psych C, Milosavjlevic Stat V, Marshall Gredis G, Sancha AM. Lung cancer and arsenic exposure in drinking water: a case-control study in northern Chile. Cad Saude Publica. 1998; 14 Suppl 3: 193-198.
113. Ferreccio C, González C, Milosavjlevic V, Marshall G, Sancha AM, Smith AH. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000; 11: 673-679.
114. Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect. 2000; 108: 655-661. (Pubitemid 30657871)
115. Guo HR. Arsenic level in drinking water and mortality of lung cancer (Taiwan). Cancer Causes Control. 2004; 15: 171-177.
116. Chen Y, Ahsan H. Cancer burden from arsenic in drinking water in Bangladesh. Am J Public Health. 2004; 94: 741-744. (Pubitemid 38560375)
117. Mostafa MG, McDonald JC, Cherry NM. Lung cancer and exposure to arsenic in rural Bangladesh. Occup Environ Med. 2008; 65: 765-768.
118. Liao CM, Shen HH, Chen CL, Hsu LI, Lin TL, Chen SC, Chen CJ J. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure. Hazard Mater. 2009; 165: 652-663.
119. Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, Duell EJ. Lung cancer in a US population with low to moderate arsenic exposure. Environ Health Perspect. 2009; 117: 1718-1723.
120. Smith AH, Ercumen A, Yuan Y, Steinmaus CM. Increased lung cancer risks are similar whether arsenic is ingested or inhaled. J Expo Sci Environ Epidemiol. 2009; 19: 343-348.
121. Higgins I, Welch K, Oh M, Bond G, Hurwitz P. In- fluence of arsenic exposure and smoking on lung cancer among smelter workers: a pilot study. Am J Ind Med. 1981; 2: 33-41. (Pubitemid 12209242)
122. Pershagen G, Wall S, Taube A, Linnman L. On the interaction between occupational arsenic exposure and smoking and its relationship to lung cancer. Scand J Work Environ Health. 1981; 7: 302-309. (Pubitemid 12196452)
123. Hertz-Picciotto I, Smith AH, Holtzman D, Lipsett M, Alexeeff G. Synergism between occupational arsenic exposure and smoking in the induction of lung cancer. Epidemiology. 1992; 3: 23-31.
124. Chen CL, Hsu LI, Chiou HY, Hsueh YM, Chen SY,Wu MM, Chen CJ. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA. 2004; 292: 2984-2990.
125. Adonis M, Martínez V, Marín P, Berrios D, Gil L. Smoking habit and genetic factors associated with lung cancer in a population highly exposed to arsenic. Toxicol Lett. 2005; 159: 32-37. (Pubitemid 41317224)
126. Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, Steinmaus C, Bates MN, Selvin S. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ Health Perspect. 2006; 114: 1293-1296. (Pubitemid 44184693)
127. Mazumdar S, Redmond CK, Enterline PE, Marsh GM, Costantino JP, Zhou SY, Patwardhan RN. Multistage modeling of lung cancer mortality among arsenic-exposed copper-smelter workers. Risk Anal. 1989; 9: 551-563. (Pubitemid 20084756)
128. Li M, Cai JF, Chiu JF. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem. 2002; 87: 29-38. (Pubitemid 34969145)
129. Wang F, Shi Y, Yadav S, Wang H. p52-Bcl3 complex promotes cyclin D1 expression in BEAS-2B cells in response to low concentration arsenite. Toxicology. 2010; 273: 12-18.
130. Dong JT, Luo XM. Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res. 1993; 302: 97-102.
131. Dong JT, Luo XM. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res. 1994; 315: 11-15.
132. Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci. 2006; 91: 372-381. (Pubitemid 43827290)
133. Martinez VD, Buys TP, Adonis M, Bentez H, Gallegos I, Lam S, Lam WL, Gil L. Arsenic-related DNA copynumber alterations in lung squamous cell carcinomas. Br J Cancer. 2010; 103: 1277-1283.
134. Chiang HS, Hong CL, Guo HR, Lee EF, Chen TY. Comparative study on the high prevalence of bladder cancer in the blackfoot disease endemic area in Taiwan. Taiwan Yi Xue Hui Za Zhi. 1988; 87: 1074-1080.
135. Cuzick J, Sasieni P, Evans S. Ingested arsenic, keratoses, and bladder cancer. Am J Epidemiol. 1992; 136: 417-421.
136. Hopenhayn-Rich C, Biggs ML, Fuchs A, Bergoglio R, Tello EE, Nicolli H, Smith AH. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996; 7: 117-124. (Pubitemid 26068042)
137. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol. 1998; 147: 660-669. (Pubitemid 28180309)
138. Kurttio P, Pukkala E, Kahelin H, Auvinen A, Pekkanen J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect. 1999; 107: 705-710. (Pubitemid 29478879)
139. Chen YC, SuHJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Christiani DC. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control. 2003; 14: 303-310. (Pubitemid 36735098)
140. Bates MN, Rey OA, Biggs ML, Hopenhayn C, Moore LE, Kalman D, Steinmaus C, Smith AH. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am J Epidemiol. 2004; 159: 381-389. (Pubitemid 38200772)
141. Chen Y, Ahsan H. Cancer burden from arsenic in drinking water in Bangladesh. Am J Public Health. 2004; 94: 741-744. (Pubitemid 38560375)
142. Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, Liaw J, Smith AH. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst. 2007; 99: 920-928. (Pubitemid 47078729)
143. Chow NH, Guo YL, Lin JS, Su JH, Tzai TS, Guo HR, Su IJ. Clinicopathological features of bladder cancer associated with chronic exposure to arsenic. Br J Cancer. 1997; 75: 1708-1710. (Pubitemid 27229067)
144. Moore LE, Smith AH, Eng C, Kalman D, DeVries S, Bhargava V, Chew K, Moore D 2nd, Ferreccio C, Rey OA, Waldman FM. Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst. 2002; 94: 1688-1696. (Pubitemid 35446837)
145. Chen CH, Chiou HY, Hsueh YM, Chen CJ, Yu HJ, Pu YS. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J Urol. 2009; 181: 547-552.
146. Chen YC, SuHJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Christiani DC. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control. 2003; 14: 303-310. (Pubitemid 36735098)
147. Hernández-Zavala A, Córdova E, Del Razo LM, Cebrián ME, Garrido E. Effects of arsenite on cell cycle progression in a human bladder cancer cell line. Toxicology. 2005; 207: 49-57. (Pubitemid 39601685)
148. Hour TC, Pu YS, Lin CC, Huang SW, Chen J, Chiu AW, Chen CJ, Huang CY. Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer. Anticancer Res. 2006; 26: 375-378. (Pubitemid 43206101)
149. Steinmaus C, BatesMN, Yuan Y, KalmanD,Atallah R, Rey OA, Biggs ML, Hopenhayn C, Moore LE, Hoang BK, Smith AH. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J Occup Environ Med. 2006; 48: 478-488. (Pubitemid 43772338)
150. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, Yang MH, Chen CJ, Hsueh YM. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol. 2007; 218: 99-106. (Pubitemid 46177163)
151. Bredfeldt TG, Jagadish B, Eblin KE, Mash EA, Gan dolfi AJ. Monomethylarsonous acid induces transformation of human bladder cells. Toxicol Appl Pharmacol. 2006; 216: 69-79. (Pubitemid 44402634)
152. Wnek SM, Jensen TJ, Severson PL, Futscher BW, Gandol fi AJ. Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure. Toxicol Sci. 2010; 116: 44-57.
153. Eblin KE, Bredfeldt TG, Buffington S, Gandolfi AJ. Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis. Toxicol Sci. 2007; 95: 321-330. (Pubitemid 46152604)
154. Escudero-Lourdes C, Medeiros MK, Crdenas- Gonzlez MC, Wnek SM, Gandolfi JA. Low level exposure to monomethyl arsonous acid-induced the overproduction of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol. 2010; 244: 162-173.
155. Wang TC, Jan KY,WangAS, Gurr JR. Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells. Mutat Res. 2007; 615: 75-86. (Pubitemid 46075134)
156. Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, Chen YT, Hsueh YM. Urinary 8-hydroxydeoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. Toxicol Appl Pharmacol. 2008; 226: 14-21.
157. Chen WT, Hung WC, Kang WY, Huang YC, Chai CY. Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase. Histopathology. 2007; 51: 785-792.
158. Regelson W, Kim U, Ospina J, Holland JF. Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer. 1968; 21: 514-522.
159. Lander JJ, Stanley RJ, Sumner HW, Boswell DC, Aach RD. Angiosarcoma of the liver associated with Fowler's solution (potassium arsenite). Gastroenterology. 1975; 68: 1582-1586.
160. Falk H, Caldwell GG, Ishak KG, Thomas LB, Popper H. Arsenic-related hepatic angiosarcoma. Am J Ind Med. 1981; 2: 43-50. (Pubitemid 12209243)
161. Kasper ML, Schoenfield L, Strom RL, Theologides A. Hepatic angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution. JAMA. 1984; 252: 3407-3408. (Pubitemid 15183452)
162. Tsai MH, Chien RN, Hsieh SY, Hung CF, Chen TC, Sheen IS. Primary hepatic angiosarcoma: report of a case involving environmental arsenic exposure. Changgeng Yi Xue Za Zhi. 1998; 21: 469-474.
163. Luo FJ, Luo ZD, Ma L. A study on the relationship between drinking water with high arsenic content and incidence of malignant tumour in Heihe Village, western part of Huhehot, Inner Mongolia. Zhonghua Liu Xing Bing Xue Za Zhi. 1995; 16: 289-291.
164. Tsai SM, Wang TN, Ko YC. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health. 1999; 54: 186-193.
165. Liaw J, Marshall G, Yuan Y, Ferreccio C, Steinmaus C, Smith AH. Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1982-1987.
166. Waalkes MP,Ward JM, Liu J, Diwan BA. Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol. 2003; 186: 7-17. (Pubitemid 36266687)
167. Lu T, Liu J, LeCluyse EL, Zhou YS, Cheng ML, Waalkes MP. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci. 2001; 59: 185-192. (Pubitemid 32117995)
168. Lai R, Wang Y, LiX, Yu RA. Effect of seleniumand arsenic on oxidative stress, DNA oxidative damage and repair in HepG2 cells. Wei Sheng Yan Jiu. 2008; 37: 645-648.
169. Guo HR, Chiang HS, Hu H, Lipsitz SR, Monson RR. Arsenic in drinking water and incidence of urinary cancers. Epidemiology. 1997; 8: 545-550 (Pubitemid 27377271)
170. Rahman MM, Chowdhury UK, Mukherjee SC, Mondal BK, Paul K, Lodh D, Biswas BK, Chanda CR, Basu GK, Saha KC, Roy S, Das R, Palit SK, Quamruzzaman Q, Chakraborti D. Chronic arsenic toxicity in Bangladesh and West Bengal, India-a review and commentary. J Toxicol Clin Toxicol. 2001; 39: 683-700. (Pubitemid 34016563)
171. Brown IR, Rush SJ. Induction of a 'stress' protein in intact mammalian organs after the intravenous administration of sodium arsenite. Biochem Biophys Res Commun. 1984; 120: 150-155. (Pubitemid 14138181)
172. Zheng XH, Watts GS, Vaught S, Gandolfi AJ. Low-level arsenite induced gene expression in HEK293 cells. Toxicology. 2003; 187: 39-48. (Pubitemid 36388757)
173. Hsueh YM, Cheng GS, Wu MM, Yu HS, Kuo TL, Chen CJ.Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status. Br J Cancer. 1995; 71: 109-114.
174. Brima EI, Jenkins RO, Lythgoe PR, Gault AG, Polya DA, Haris PI. Effect of fasting on the pattern of urinary arsenic excretion. J Environ Monit. 2007; 9: 98-103. (Pubitemid 46072474)
175. Vahter ME. Interactions between arsenic-induced toxicity and nutrition in early life. J Nutr. 2007; 137: 2798-2804. (Pubitemid 350255316)
176. Gamble MV, Liu X, Ahsan H, Pilsner R, Ilievski V, Slavkovich V, Parvez F, Levy D, Factor-Litvak P, Graziano JH. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ Health Perspect. 2005; 113: 1683-1688. (Pubitemid 41794261)
177. Gamble MV, Liu X, Ahsan H, Pilsner JR, Ilievski V, Slavkovich V, Parvez F, Chen Y, Levy D, Factor-Litvak P, Graziano JH. Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. Am J Clin Nutr. 2006; 84: 1093-1101. (Pubitemid 44730380)
178. Heck JE, Nieves JW, Chen Y, Parvez F, Brandt-Rauf PW, Graziano JH, Slavkovich V, Howe GR, Ahsan H. Dietary intake of methionine, cysteine, and protein and urinary arsenic excretion in Bangladesh. Environ Health Perspect. 2009; 117: 99-104.
179. Pilsner JR, Liu X, Ahsan H, Ilievski V, Slavkovich V, Levy D, Factor-Litvak P, Graziano JH, Gamble MV. Genomic methylation of peripheral blood leukocyte DNA: influences of arsenic and folate in Bangladeshi adults. Am J Clin Nutr. 2007; 86: 1179-1186. (Pubitemid 47538325)
180. Li L, Ekström EC, Goessler W, Lönnerdal B, Nermell B, Yunus M, Rahman A, El Arifeen S, Persson LA, Vahter M. Nutritional status has marginal influence on the metabolism of inorganic arsenic in pregnant Bangladeshi women. Environ Health Perspect. 2008; 116: 315-321. (Pubitemid 351395598)
181. Shi H, Shi X, Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem. 2004; 255: 67-78. (Pubitemid 38159766)
182. Hei TK, Filipic M. Role of oxidative damage in the genotoxicity of arsenic. Free Radic Biol Med. 2004; 37: 574-581. (Pubitemid 38993505)
183. Avani G, Rao MV. Genotoxic effects in human lymphocytes exposed to arsenic and vitamin A. Toxicol In Vitro. 2007; 21: 626-631. (Pubitemid 46550747)
184. Avani G, Rao MV. In vitro genotoxicity assays to evaluate the role of vitamin A on arsenic in human lymphocytes. Ecotoxicol Environ Saf. 2009; 72: 635-638.
185. Karasavvas N, Cárcamo JM, Stratis G, Golde DW. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood. 2005; 105: 4004-4012.
186. Bongiovanni GA, Soria EA, Eynard AR. Effects of the plant flavonoids silymarin and quercetin on arsenite-induced oxidative stress in CHO-K1 cells. Food Chem Toxicol. 2007; 45: 971-976. (Pubitemid 46509817)
187. Yang J, Li H, Chen YY, Wang XJ, Shi GY, Hu QS, Kang XL, Lu Y, Tang XM, Guo QS, Yi J. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med. 2004; 37: 2027-2041. (Pubitemid 39491322)
188. Chowdhury R, Dutta A, Chaudhuri SR, Sharma N, Giri AK, Chaudhuri K. In vitro and in vivo reduction of sodium arsenite induced toxicity by aqueous garlic extract. Food Chem Toxicol. 2008; 46: 740-751. (Pubitemid 350297554)
189. Sinha D, Dey S, Bhattacharya RK, RoyM. In vitro mitigation of arsenic toxicity by tea polyphenols in human lymphocytes. J Environ Pathol Toxicol Oncol. 2007; 26: 207-220.
190. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol. 2010; 29: 513-524.
191. Tiwari H, Rao MV. Curcumin supplementation protects from genotoxic effects of arsenic and fluoride . Food Chem Toxicol. 2010; 48: 1234-1238.
192. Xu Y,Wang H,Wang Y, Zheng Y, Sun G. Effects of folate on arsenic toxicity in Chang human hepatocytes: involvement of folate antioxidant properties. Toxicol Lett. 2010; 195: 44-50.
193. Pant HH, Rao MV. Evaluation of in vitro anti-genotoxic potential of melatonin against arsenic and fluoride in human blood cultures. Ecotoxicol Environ Saf. 2010; 73: 1333-1337.
194. Chung CJ, Pu YS, Chen YT, Su CT,Wu CC, Shiue HS, Huang CY, Hsueh YM. Protective effects of plasma alpha- tocopherols on the risk of inorganic arsenic-related urothelial carcinoma. Sci Total Environ. 2011; 409: 1039-1045.
195. Sweins A. Protective effect of selenium against arsenicinduced chromosomal damage in cultured human lymphocytes. Hereditas. 1983; 98: 249-252. (Pubitemid 13078045)
196. Hu GG. Investigation of protective effect of selenium on genetic materials among workers exposed to arsenic. Zhonghua Yu Fang Yi Xue Za Zhi. 1989; 23: 286-288.
197. Mo J, Xia Y, Wade TJ, Schmitt M, Le XC, Dang R, Mumford JL. Chronic arsenic exposure and oxidative stress: OGG1 expression and arsenic exposure, nail selenium, and skin hyperkeratosis in Inner Mongolia. Environ Health Perspect. 2006; 114: 835-841. (Pubitemid 43871730)
198. Chen Y, Hall M, Graziano JH, Slavkovich V, van Geen A, Parvez F, Ahsan H. A prospective study of blood selenium levels and the risk of arsenic-related premalignant skin lesions. Cancer Epidemiol Biomarkers Prev. 2007; 16: 207-213. (Pubitemid 46383336)
199. Zeng H, Uthus EO, Combs GF. Mechanistic aspects of the interaction between selenium and arsenic. J Inorg Biochem. 2005; 99: 1269-1274. (Pubitemid 40726022)
200. Huang Z, Pei Q, Sun G, Zhang S, Liang J, Gao Y, Zhang X. Low selenium status affects arsenic metabolites in an arsenic exposed population with skin lesions. Clin Chim Acta. 2008 ; 387: 139-144. (Pubitemid 350050948)